Clinical data
ATC code None
CAS Number 757950-09-7
PubChem (CID) 10331863
ChemSpider 8507323
Chemical and physical data
Formula C15H13FN2
Molar mass 240.276 g/mol
3D model (Jmol) Interactive image

Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.[1][2] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.[2][3][4]

See also


  1. Annual Reports in Medicinal Chemistry. Academic Press. 31 December 2012. pp. 80–. ISBN 978-0-12-397214-9.
  2. 1 2 Murray B. Stein; Thomas Steckler (30 July 2010). Behavioral Neurobiology of Anxiety and Its Treatment. Springer Science & Business Media. pp. 397–. ISBN 978-3-642-02912-7.
  3. Celia Dominguez (18 November 2010). Neurodegenerative Diseases. Springer Science & Business Media. pp. 120–. ISBN 978-3-642-16758-4.
  4. Nicholas J. Shaheen (25 March 2013). Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics,. Elsevier Health Sciences. pp. 119–. ISBN 1-4557-7175-9.

This article is issued from Wikipedia - version of the 10/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.